Impact of Chewing Gum With CPP-ACP on Tooth Mineralisation in Situ

October 15, 2021 updated by: Mondelēz International, Inc.

Impact of Chewing Gum Containing CPP-ACP on Tooth Mineralisation, Using an in Situ Appliance in Healthy Subjects

Monocentric, randomised, double-blind, cross-over controlled study with two arms.

This study aims to analyse the impact on mineralisation of Sugar Free Gum (SFG) containing CPP-ACP in healthy adults.

Study Overview

Detailed Description

There is some promising evidence in the literature to support a significant favourable impact of the consumption of Sugar Free Gum (SFG) containing casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) on tooth mineralisation and especially on the promotion of tooth remineralisation, over and above the well-established role of regular SFG, in humans.

This study is a monocentric, randomised, double-blind, cross-over and controlled study. The research hypothesis is that chewing a SFG containing CPP-ACP from Recaldent will better remineralise the enamel in healthy subjects compared with regular SFG, after 2 weeks of gum chewing 5 times a day for 20 minutes within 5 minutes after each meal and snack occasion, with a CPP-ACP dose of 18.8 mg per SFG. This will be studied with an in situ model study, with palatal appliances bearing recessed (1,5mm) human demineralised enamel blocks with caries-like lesions (subsurface lesions), which should be worn 24 h a day by the subjects, including during eating and drinking (but the appliances should be removed for daily oral hygiene procedure and cleaning of the appliance itself). Each appliance will contain two types of the demineralised enamel blocks: half of the blocks will contain shallow subsurface lesions (Carbopol method) and the other half reflecting deeper subsurface lesions (hydroxy-ethyl cellulose method). Both types of lesions have been the subject of oral research interest, as both shallow and deep lesions are involved in caries genesis. Changes in mineralisation of the lesions will be assessed using Transverse Microradiography (TMR).

Study Type

Interventional

Enrollment (Anticipated)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 53 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy adults aged between 18 and 55 years old (inclusive)
  • Subject has read, signed and received a copy of the Informed Consent prior to initiation of study procedures
  • Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits at their appointed time, and to use the product as per instructions
  • Subject is in good general health based on medical history and oral soft and hard tissue examination
  • Subject with normal salivary flow (unstimulated flow rate ≥0.3ml/min)
  • Subject not disliking the taste of the SFG provided
  • Subject with stable dietary habits and willing to consume 3 main meals per day with two extra-prandial intakes
  • Healthy adults with a BMI value between 20 and 30 kg/m²

Exclusion Criteria:

General criteria

  • Subject under legal protection measure
  • Subject deprived of liberty by a court or an administrative decision
  • Subject currently participating in another study or being in the exclusion period of another study

Biological, therapeutic and medical criteria

  • Subject is pregnant, lactating or intend to become pregnant during the course of the clinical study based on oral interview only, as pregnancy may interfere with the outcome of the study
  • Subject has a systemic health condition and disorders (such as diabetes HIV positive, AIDS and systemic lupus erythematosis) that could affect the outcome of the study at the discretion of the Investigator
  • Any active oral condition, such as caries, periodontal disease, chronic dental neglect or any oral pathology including xerostomia determined by oral evaluation and subject history that in the opinion of the dental examiner could affect the outcome of the study
  • Subject has full or partial dentures or any orthodontic appliances (i.e. braces or use of night guards) or tongue or mouth piercing
  • Use of other oral care products except the one provided by study team during the wash out period or during the treatment period
  • Participation in a research study within the last 30 days
  • Subjects treated with antibiotics during the last 30 days or other medications, which in the opinion of the Investigator might influence the study outcome
  • Subjects with a history of sensitivity or allergies to ingredients in the study products or allergens present in the production facility (facility which also handles milk, egg, soy, peanut, tree nuts, wheat, fish, crustacean, mollusk, lupine, sesame, seeds, sulphites)Subjects with any concurrent illness, such as a cold, flu, upper respiratory infection, sinusitis or other infectious conditions
  • Subjects under a restrictive diet or with a planned weight loss program during the study
  • Subjects with severe eating disorders (e.g. anorexia nervosa, binge eating disorder and bulimia)
  • Subjects without stable dietary habits or with specific dieting regime, for instance Atkins diet, gluten-free diet and additional specific diets at the discretion of the Investigator
  • Subjects who smokes or vapes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Sugar free gum without CPP-ACP
Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
Active Comparator: Sugar free gum with CPP-ACP
Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
Other Names:
  • Recaldent

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Compare the relative mineral weight content measured by Transverse Microradiography (DeltaZd-DeltaZr) on subsurface lesions created by Carbopol method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Compare the densitometric profile of the demineralised lesion (Delta Zd) measured by Transverse Microradiography on subsurface lesions created by Carbopol method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the densitometric profile of the remineralised lesion (Delta Zr) measured by Transverse Microradiography on subsurface lesions created by Carbopol method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the percent mineral change (%R) measured by Transverse Microradiography on subsurface lesions created by Carbopol method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the lesion depth (LD) measured by Transverse Microradiography on subsurface lesions created by Carbopol method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the change in lesion depth (LDd - LDr) after treatment measured by Transverse Microradiography on subsurface lesions created by Carbopol method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the relative mineral weight content measured by Transverse Microradiography (DeltaZd-DeltaZr) on subsurface lesions created by hydroxy-ethyl cellulose (HEC) method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the densitometric profile of the demineralised lesion (Delta Zd) measured by Transverse Microradiography on subsurface lesions created by hydroxy-ethyl cellulose (HEC) method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the densitometric profile of the remineralised lesion (Delta Zr) measured by Transverse Microradiography on subsurface lesions created by hydroxy-ethyl cellulose (HEC) method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the percent mineral change (%R) measured by Transverse Microradiography on subsurface lesions created by hydroxy-ethyl cellulose (HEC) method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the lesion depth (LD) measured by Transverse Microradiography on subsurface lesions created by hydroxy-ethyl cellulose (HEC) method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compare the change in lesion depth (LDd - LDr) after treatment measured by Transverse Microradiography on subsurface lesions created by hydroxy-ethyl cellulose (HEC) method
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compliance to the number of chewing-gum consumption per day
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compliance to the length of chewing-gum occasion
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Compliance to the number of meal and snack consumption per day
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Evaluation the compliance to oral appliance wearing (length of appliance wearing per day)
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Evaluation the compliance to oral hygiene compliance: number of oral procedures per day
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period
Evaluation the compliance to oral hygiene compliance: weight of unused toothpaste
Time Frame: After 2 weeks intervention period
Comparison between the 2 groups
After 2 weeks intervention period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Susan M. Higham, Prof., The University of Liverpool

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

October 1, 2021

Primary Completion (Anticipated)

June 1, 2022

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

May 22, 2019

First Submitted That Met QC Criteria

May 29, 2019

First Posted (Actual)

June 3, 2019

Study Record Updates

Last Update Posted (Actual)

October 18, 2021

Last Update Submitted That Met QC Criteria

October 15, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tooth Demineralization

Clinical Trials on Sugar free gum without CPP-ACP

3
Subscribe